When considering that PD-1 and PD-L1 expression is associated with immunotherapy response [101] and that their gene promoter DNA methylation levels can potentially predict their expression status, it seems that therapies to modulate epigenetic changes in MCC may help enable improved responses to immunotherapy. This evidence concerns the gene CD274 and Merkel cell skin cancer.